SLU-PP-332 and BAM15: The Complete Guide to These Research Compounds

Quick Facts

What SLU-PP-332 and BAM15 Do vs. How They Work

What They Do: Functional Outcomes

Before getting into mechanisms, a clarification that matters: SLU-PP-332 and BAM15 are not peptides. They are small-molecule research chemicals. Peptides are chains of amino acids (the building blocks proteins are made from). Gastric acid (the digestive fluid in your stomach) and digestive enzymes (proteins that break down food molecules) dismantle peptide chains before they can reach systemic circulation. That degradation is why actual peptides require injection to be effective. SLU-PP-332 and BAM15 have no amino acid sequence and are designed as small molecules that survive the gastrointestinal environment intact. The "peptide" label attached to them in market discussions reflects how they are sold and categorized commercially, alongside peptide therapies in the biohacking and metabolic health space, not their actual molecular nature. That distinction is part of understanding why these compounds behave differently from the rest of the compounds covered in this library.

With that established, here is what preclinical research and anecdotal community documentation suggest these compounds do:

• Increases resting energy expenditure: the body burns more calories at rest, without increases in physical activity
• Reduces fat mass in obese animal models, without changes in food intake or lean tissue
• Improves glucose tolerance: enhances the body's ability to clear glucose from the bloodstream
• Activates metabolic gene programs normally triggered by aerobic exercise, which is the basis for the "exercise mimetic" classification
• Increases thermogenesis: generates heat as a byproduct of increased metabolic activity, particularly from BAM15's uncoupling mechanism
• Upregulates fatty-acid oxidation: increases the rate at which stored fat is used as fuel

How They Work: Mechanism of Action

ERRalpha Activation by SLU-PP-332 (Evidence: Animal)

SLU-PP-332 is a synthetic agonist of estrogen-related receptor alpha (ERRalpha), a nuclear receptor that functions as a master regulator of metabolic gene expression. A nuclear receptor is a protein inside the cell that, when activated, travels to the cell's nucleus and turns genes on or off. When ERRalpha is activated, it switches on a suite of genes governing fatty-acid oxidation, mitochondrial biogenesis (the process of building new mitochondria, the cell's energy-producing structures), and aerobic energy production. These are the same gene programs that physical exercise activates in metabolic tissues like skeletal muscle, adipose tissue, and liver. SLU-PP-332 produces this transcriptional effect (gene-switching activity) without requiring physical movement, which is why it is described as an exercise mimetic. The primary preclinical study confirmed that ERRalpha activation translated to measurable increases in resting energy expenditure and reductions in fat mass in obese mouse models.

Mitochondrial Uncoupling by BAM15 (Evidence: Preclinical, mechanistic and cell-based)

BAM15 is a protonophore (a molecule that creates an alternative pathway for charged particles called protons to cross a cellular membrane). Normally, protons are pumped across the inner mitochondrial membrane during fuel oxidation, building up a gradient that drives ATP synthase (the molecular machine that produces ATP, the cell's primary energy currency). BAM15 disrupts that process by allowing protons to return across the membrane without going through ATP synthase. The result is that fuel keeps being oxidized (fat and glucose keep burning) but a portion of the energy that would have become ATP instead escapes as heat. Cells compensate for the reduced ATP yield by burning more substrate, which is the mechanism behind the increased energy expenditure.

Theoretical Complementarity of the Combination (Evidence: Mechanistic inference, not validated in published combination research)

The rationale for pairing these two compounds is mechanistic. SLU-PP-332 works upstream: it activates the transcriptional programs (the gene-switching instructions) that build metabolic machinery, increasing the cell's capacity for fuel oxidation and mitochondrial activity. BAM15 works downstream: it drives increased substrate throughput through that machinery by creating the proton leak. The theoretical argument is that one compound builds the engine capacity while the other pushes more fuel through the engine. Whether that theoretical complementarity produces synergistic, additive, or simply redundant effects in humans has not been tested in any published combination study.

Molecular Profile

Important note on SLU-PP-332 molecular formula: Two of the most prominent research chemical suppliers report different molecular formulas for SLU-PP-332. Bio-Techne/Tocris reports C18H14N2O2, while Cayman Chemical reports C18H14N2O. This one-atom oxygen discrepancy is not a rounding issue. It reflects genuine uncertainty about the compound's identity at the supplier level, and it is a concrete reason why third-party certificate of analysis documentation matters for any purchase of this compound.

Structure reference: View SLU-PP-332 on PubChem (CID 5404083) - Publishing team: retrieve 2D structure image from PubChem CID 5404083.

Common Uses & Conditions for SLU-PP-332 and BAM15

Metabolic Syndrome and Obesity

The primary preclinical application of SLU-PP-332 is obesity and metabolic syndrome. The published mouse study used obese animal models and measured fat mass, glucose tolerance, and resting energy expenditure as primary outcomes. All three are core features of metabolic syndrome. The ERRalpha activation mechanism is directly relevant to the pathophysiology of obesity, which involves reduced mitochondrial activity, impaired fatty-acid oxidation, and dysregulated glucose metabolism. BAM15 adds a thermogenic mechanism that increases total caloric expenditure independently of the transcriptional changes SLU-PP-332 produces. In biohacking and research communities, this combination is primarily discussed in the context of fat loss and metabolic health optimization. (Evidence: Preliminary, animal data - Billon et al., 2024)

Glucose Regulation and Insulin Sensitivity

ERRalpha plays a regulatory role in genes governing glucose uptake and oxidative metabolism. The obese mouse study found meaningful improvement in glucose tolerance in SLU-PP-332-treated animals compared to untreated obese controls. Notably, this improvement occurred without changes in food intake, suggesting a metabolic rather than behavioral mechanism. BAM15's thermogenic mechanism also influences glucose utilization, as cells burning more substrate for heat must draw on both fat and glucose reserves. The potential relevance to insulin resistance and type 2 diabetes is the focus of significant theoretical interest in secondary sources, though no human clinical study has tested either compound in people with diabetes or prediabetes. (Evidence: Preliminary, animal data - Billon et al., 2024)

Exercise Mimicry and Metabolic Fitness

The "exercise mimetic" framing for SLU-PP-332 is scientifically meaningful, not just marketing language. ERRalpha is a transcription factor (a protein that controls which genes get switched on or off in a cell) that exercise activates, and SLU-PP-332 activates it directly through a different upstream signal. This means the compound can trigger some of the same gene expression changes that exercise produces, including upregulation of mitochondrial biogenesis, fatty-acid oxidation enzymes, and aerobic energy production pathways, without requiring physical activity. University of Florida coverage of this research specifically highlighted its potential relevance for populations who cannot exercise due to mobility limitations, chronic illness, or age-related decline. The scope of the mimicry is molecular and metabolic, not cardiovascular or mechanical. (Evidence: Preliminary - University of Florida, 2023)

Longevity and Metabolic Anti-Aging

Secondary sources and biohacking communities discuss SLU-PP-332 in longevity contexts, drawing on the connection between ERRalpha activity, mitochondrial health, and aging. Mitochondrial function declines with age, and ERRalpha-regulated gene programs are part of the mitochondrial biogenesis and quality-control machinery that keeps cellular energy production efficient over time. The theoretical longevity argument is that maintaining ERRalpha activity through pharmacological agonism could slow age-related metabolic decline. This is speculative: no longevity-focused study has been published for either compound. The mechanistic rationale is coherent, however, and explains why these compounds appear in longevity-adjacent discussions. (Evidence: Mechanistic inference, secondary sources)

Where This SLU-PP-332 and BAM15 Guide Comes From

Results People Report: Outcome Timelines

A necessary framing note before the timelines: the outcome data below comes from anecdotal user reports in community documentation, not from published clinical studies. No controlled trial has measured the timing of human outcomes for either compound. These patterns reflect what users in the research community describe; they are orientation points, not predictions.

Thermogenic and Metabolic Activity

• Day 1-3: Increased body warmth and perspiration are the most commonly reported early signals, consistent with BAM15's immediate thermogenic mechanism. Some users describe a mild energy shift: feeling warmer at rest and during ordinary activity.
• Week 1-2: Increased sweating during exercise and at rest continues. Some users report mild initial fatigue or GI adjustment during this period.
• Week 2-4: Early thermogenic effects stabilize for most users. Energy levels in anecdotal reports are described as normalizing after the initial adjustment period.

Body Composition and Metabolic Health

• Week 1-4: No significant body composition changes are typically reported in early weeks. Most anecdotal users note this is too early to assess fat loss outcomes.
• Week 4-8: Body composition changes, when reported, begin to appear in this window in community protocol logs. Effects appear most pronounced when combined with caloric control and exercise.
• Week 8-12: The most commonly referenced window for meaningful outcome assessment in community documentation. Anecdotal reports of fat loss and improved body composition concentrate in this range.

Administration Methods for SLU-PP-332 and BAM15

Oral Capsules

Oral capsule is the only commercial format identified for SLU-PP-332 and BAM15. This is a meaningful distinction from most compounds discussed in the peptide library. Both SLU-PP-332 and BAM15 are small molecules, not peptides. Small molecules can be designed for oral bioavailability in ways that peptides cannot. Gastric acid (the digestive fluid in your stomach) and digestive enzymes (proteins that break down food molecules) dismantle peptide chains before they reach systemic circulation, which is why peptides require injection. Small molecules like SLU-PP-332 and BAM15 can survive the GI environment and be absorbed into the bloodstream intact. The primary preclinical studies administered SLU-PP-332 via oral gavage (a method of delivering compounds directly into the stomach of a research animal, confirming the oral route reaches systemic circulation) in mice and achieved measurable systemic metabolic effects. Standard commercial products are sold as 60-capsule bottles containing the blend at a standard ratio of 250 mcg SLU-PP-332 and 50 mg BAM15 per capsule. Some vendors offer alternative ratios or standalone SLU-PP-332 without BAM15. No injectable, nasal, or topical formulations of either compound have been identified in current commercial market research; those routes are not documented for either compound.

Dosing & Cycle Length for SLU-PP-332 and BAM15

Overall dosing spectrum: No validated human dose exists for either SLU-PP-332 or BAM15. The animal study doses are not directly applicable to humans. What circulates in the research community and among self-experimenters are anecdotal ranges that have not been confirmed by controlled human trials.

Anecdotal human ranges reported in community documentation:

• SLU-PP-332: 100-800 mcg/day reported across various community sources, with 200-250 mcg/day appearing most commonly in documented personal protocols
• BAM15: 50 mg per dose unit is the standard in commercial blend formulations; standalone dosing ranges are not consistently documented

Commercial formulation context: The standard commercial capsule blend contains 250 mcg SLU-PP-332 and 50 mg BAM15 per capsule. This ratio reflects the potency difference between the two compounds. One to two capsules per day appears to be the most commonly referenced starting point in anecdotal sources, though this is not a validated protocol.

How the goal shifts where you land:

• Lower end of the anecdotal SLU-PP-332 range (100-250 mcg): More commonly associated with conservative introductory use and longevity-adjacent protocols where users want minimal perturbation of normal mitochondrial function
• Mid range (250-500 mcg): The most frequently referenced range in community protocol logs for fat loss and metabolic health goals
• Higher end (500-800 mcg): Reported by a smaller number of users in fat loss contexts; individual anecdotal accounts document personal experiments at higher doses with the caveat that these are individual reports, not clinical recommendations

Frequency: Once daily is the most commonly described pattern in available community documentation; the standard commercial capsule format appears designed for once-daily use

Cycle length: Anecdotal reports describe cycles ranging from 4 to 12 weeks. A pattern of 6 weeks on followed by 6 weeks off appears in at least one documented personal protocol. An 8 to 12 week range appears in practitioner-adjacent secondary sources. No validated cycle length exists. The primary mouse study used 28-day and 8-week treatment windows, which provides the only structured duration data available from an animal model.

Loading protocols: No loading protocol has been documented for either compound in available sources.

Vial Sizes, Costs & Quality for SLU-PP-332 and BAM15

Common formats: Unlike most compounds in the peptide therapy space, SLU-PP-332 and BAM15 are not sold as injectable vials requiring reconstitution. The commercial format is oral capsules. Standard bottle sizes are 60 capsules, which at once-daily dosing provides a 60-day supply of the standard blend.

Typical cost range: Commercial capsule blends of SLU-PP-332 and BAM15 range from approximately $130 to $305 per 60-capsule bottle at current U.S. market pricing, depending on supplier, formulation, and quality documentation included. The roughly 2x price spread across the market for what appear to be equivalent formulations reflects significant variation in manufacturing standards, testing documentation, and overhead, not necessarily any difference in labeled content.

Standard blend ratio: 250 mcg SLU-PP-332 + 50 mg BAM15 per capsule is the most commonly observed commercial formulation. Some vendors offer alternative ratios or standalone SLU-PP-332 capsules without BAM15.

Storage:

• Capsule storage: Store in a cool, dry environment away from direct light. At least one vendor specifies storage at -10 degrees C for the capsule product; others recommend standard cool, dry conditions. If cold storage is specified by the manufacturer, follow that guidance.
• Shelf life: Typically documented at 12-24 months for sealed capsule products stored per manufacturer instructions; verify against the certificate of analysis or product insert from your specific supplier.

Appearance: These are encapsulated oral products; appearance questions that apply to reconstituted injectable peptides (clarity, color, particulates) do not apply here. What matters is that capsules are intact, uniform in appearance, and free of obvious damage or degradation. Any unusual odor from opened capsules or visible capsule breakdown warrants discarding the product.

Signs of degradation: Damaged capsule shells, unusual or chemical odor on opening, visible discoloration or moisture damage inside capsules, or product stored outside recommended temperature and humidity ranges.

Quality Considerations

Research chemicals sold in capsule format occupy a category with even less regulatory oversight than injectable research compounds. Capsules contain a powder inside an opaque shell, and without a certificate of analysis from an independent third-party testing lab, a buyer has no way to verify that the capsule contains what the label claims, in the quantities claimed. The SLU-PP-332 molecular formula discrepancy between two major research chemical suppliers (one reporting C18H14N2O2, the other reporting C18H14N2O) is a concrete example of the quality uncertainty that exists even at the compound identification level. U.S.-based suppliers with documented manufacturing standards, verifiable certificates of analysis, and third-party purity testing offer meaningfully more assurance than overseas vendors with no quality documentation. The roughly 2x price difference between the cheapest and most expensive options in this market is consistent with the cost of actually testing what you are selling.

Side Effects & Contraindications

Side Effect Spectrum

Important context on this table: The Common and Less Common columns reflect anecdotal human reports and mechanistic inference from the uncoupling mechanism. The Rare/Serious column reflects theoretical mechanistic risks from the drug class or high-dose animal data; these have not been documented in human use of BAM15 specifically. The entire table is extrapolated from preclinical and mechanistic sources, not human clinical trial adverse event data.

Contraindications

No formally established contraindications exist for either compound based on clinical trial evidence. The following represent precautionary guidance derived from mechanistic reasoning and the absence of safety data in specific populations:

• Cardiovascular disease: Mitochondrial uncoupling increases metabolic rate and can transiently elevate heart rate; insufficient data to confirm safety in people with cardiac conditions
• Liver disease: Minor liver enzyme changes were observed in mouse studies at high doses of SLU-PP-332; insufficient data to confirm safety in people with hepatic compromise
• Hyperthyroidism or heat-intolerance conditions: BAM15's thermogenic mechanism compounds existing heat production; not studied in this population
• Concurrent use of stimulants, thermogenic compounds, or other mitochondrial-active agents: Mechanistic overlap creates unpredictable interaction risk; insufficient data to characterize this combination

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No safety data; use is not appropriate without medical supervision
• Pediatric use: Not studied in any pediatric population; not appropriate without medical supervision
• People with diabetes or active glucose-regulation disorders: ERRalpha activation affects glucose metabolism; interaction with diabetes medications is theoretically plausible and unstudied
• People using GLP-1 agonists or other metabolic medications: Pathway overlap creates potential for interaction or compounded metabolic effects; no interaction data exists

Red Flags: Stop Use and Seek Medical Attention If

• Sustained or significant increase in body temperature that does not resolve with rest and cooling
• Chest pain, palpitations, or irregular heartbeat
• Severe or persistent nausea, vomiting, or GI distress
• Unusual fatigue that does not improve with rest or reduced dose
• Yellowing of skin or eyes, or significant abdominal discomfort (potential hepatic signals)
• Any symptom that feels clinically serious and does not resolve promptly

Drug and Compound Interactions

No formal drug interaction studies have been conducted for SLU-PP-332 or BAM15. From a mechanistic standpoint, the most significant theoretical interaction risk involves compounds that also affect metabolic rate, thermogenesis, or mitochondrial function. This includes other uncoupling agents, thyroid medications, stimulants, and diabetes medications that work through AMPK (an enzyme that acts as a cellular energy sensor) or glucose transporter pathways. The historical context for mitochondrial uncouplers is relevant: 2,4-dinitrophenol (DNP), a structurally different uncoupler used in the 1930s, caused deaths primarily through hyperthermia and interaction with other thermogenic agents. BAM15 is claimed to have a different and more selective safety profile in preclinical work, but that distinction has not been validated in human trials. The class-level risk of additive thermogenic effects from combining multiple metabolic activators warrants serious caution.

Research Evidence & Studies

Pharmacokinetics & Metabolism

Absorption and Bioavailability: SLU-PP-332

SLU-PP-332 is a small molecule designed for oral delivery. The primary preclinical studies administered it orally and achieved measurable systemic effects on energy expenditure, fat mass, and glucose tolerance. This confirms oral bioavailability sufficient to produce biological effects. Quantitative human bioavailability data has not been published.

Absorption and Bioavailability: BAM15

BAM15 is similarly a small molecule administered orally in preclinical studies. Its mechanism of action at the mitochondrial membrane requires systemic distribution to target tissues, which the preclinical evidence suggests is achieved through oral dosing. Specific bioavailability percentages have not been published in available sources.

Distribution

No published data on blood-brain barrier penetration for either compound is available in reviewed sources. SLU-PP-332's primary target tissues (adipose, skeletal muscle, and liver) are peripheral, consistent with its metabolic mechanism. BAM15's target is the inner mitochondrial membrane, which is present in every cell containing mitochondria; tissue selectivity is not a feature of its mechanism.

Half-Life

Half-life data for SLU-PP-332 in humans has not been published. Mouse pharmacokinetic profiles suggest a duration consistent with once-daily dosing being sufficient to maintain ERRalpha activation in animal studies. BAM15 half-life data is similarly unavailable from reviewed human or pharmacokinetic studies.

Metabolism and Elimination

Metabolism and elimination pathways for both compounds have not been characterized in published human pharmacokinetic studies. This is a significant data gap. Without knowing how these compounds are metabolized, the risk of accumulation, interaction with hepatic CYP450 enzymes (a family of liver enzymes responsible for breaking down most drugs and foreign compounds), and the behavior of metabolites cannot be assessed.

Mechanistic Research

ERRalpha Activation by SLU-PP-332 (Evidence: Animal - Billon et al., 2024, JPET)

The primary peer-reviewed study on SLU-PP-332 used obese mouse models treated for 28 days. Activation of ERRalpha produced measurable upregulation of metabolic gene programs associated with aerobic exercise: genes governing fatty-acid oxidation, mitochondrial biogenesis, and aerobic energy production. This mechanistic effect is what gives SLU-PP-332 its "exercise mimetic" classification. The study measured resting energy expenditure, glucose tolerance, fat mass, lean mass, food intake, and locomotor activity. It found significant changes in metabolic markers with no changes in behavior or lean tissue.

Mitochondrial Uncoupling by BAM15 (Evidence: Preclinical, mechanistic and cell-based)

BAM15 functions as a protonophore, dissipating the electrochemical proton gradient (the energy-storing charge difference across the inner mitochondrial membrane that drives ATP production) across the inner mitochondrial membrane. This gradient, called the mitochondrial membrane potential, is the driving force for ATP synthesis. When BAM15 provides an alternative proton pathway, the gradient is partially dissipated as heat rather than captured as ATP. Cells respond by increasing substrate oxidation, burning more glucose and fatty acids, to maintain ATP production. Unlike DNP (an earlier and far more toxic mitochondrial uncoupler), BAM15 is claimed to have a higher therapeutic ratio in preclinical work, meaning a wider margin between effective and toxic doses.

Glucose Tolerance Improvement (Evidence: Animal - Billon et al., 2024, JPET)

The obese mouse study measured glucose tolerance directly and found meaningful improvement in SLU-PP-332-treated animals compared to untreated obese controls. This is mechanistically consistent with ERRalpha's role in regulating genes involved in glucose uptake and oxidative metabolism. The improvement in glucose tolerance occurred independently of changes in food intake, suggesting the mechanism is metabolic rather than appetite-mediated. Whether this effect is present in humans with insulin resistance or type 2 diabetes has not been tested in any published clinical study.

Condition-Focused Research

Obesity and Adiposity Reduction {#research-obesity}

The Billon et al. (2024) mouse study used obese models and measured fat mass as a primary outcome. SLU-PP-332-treated animals showed reduced adiposity compared to controls over the 28-day treatment period, with no change in lean mass. This means the weight effect was specific to fat rather than reflecting muscle loss or general tissue wasting. Food intake was also unchanged, which distinguishes this mechanism from appetite suppression approaches. The reduction in fat mass without appetite suppression is what makes ERRalpha activation mechanistically distinct from GLP-1 agonists and similar compounds. (Evidence: Preliminary, animal data - Billon et al., 2024, JPET)

Exercise Mimicry and Metabolic Gene Activation {#research-exercise}

University of Florida coverage of the SLU-PP-332 research specifically highlighted the exercise-mimetic framing, noting that the compound activated gene programs normally triggered by aerobic exercise. This coverage followed publication of the primary preclinical findings and brought mainstream attention to potential applications in populations who cannot exercise. The research framing here is important: SLU-PP-332 does not replicate the mechanical, cardiovascular, or neurological effects of exercise. It mimics specific transcriptional programs that exercise activates in metabolic tissues. The scope of the mimicry is molecular, not systemic. (Evidence: Preliminary - University of Florida, 2023)

Metabolic Safety Profile: Preclinical Data {#research-safety-profile}

The primary mouse study reported no severe adverse effects over 28 days. Minor changes in plasma cholesterol and liver enzymes were observed but described as not clinically significant in the study context. No toxicity or safety study extending beyond 8 weeks has been identified for SLU-PP-332, and no comparable structured safety data exists for BAM15 outside of cell-based and mechanistic work. (Evidence: Preliminary, animal data - Billon et al., 2024, JPET)

Safety and Tolerability Research

The available safety data is limited to the 28-day mouse study and review-level commentary. No controlled human safety study has been published for SLU-PP-332, BAM15, or their combination. The mouse study found only minor changes in plasma cholesterol and liver enzymes, with no organ toxicity, no changes in behavior or food intake, and no mortality. University of Florida reporting on the research confirmed no severe side effects were observed in animal studies. For BAM15, the primary safety consideration is class-based: the mitochondrial uncoupler drug class carries inherent thermogenic risk at excessive doses, as established by the historical DNP experience. BAM15's claimed safety advantage over DNP rests on preclinical data that has not been extended to human trials.

Research Limitations

The evidence base for SLU-PP-332 and BAM15 has specific and significant gaps. Published research on SLU-PP-332 consists primarily of a single peer-reviewed mouse study and review-level publications. No human clinical trial has been registered or completed for either compound as of July 2026. BAM15 has no peer-reviewed clinical trial data at any stage. The combination of SLU-PP-332 and BAM15 has never been studied in a controlled setting; its theoretical synergy is mechanistically plausible but has not been tested. The longest duration of SLU-PP-332 data in any model is 8 weeks in mice. The molecular formula discrepancy between major suppliers adds a layer of fundamental uncertainty about what is even being researched commercially. Human pharmacokinetics, metabolic fate, optimal dose, drug interactions, and long-term safety are all entirely unknown.

Regulatory & Sports Status

FDA status: Neither SLU-PP-332 nor BAM15 is approved by the FDA for any human therapeutic use. Neither has been designated as an Investigational New Drug with a registered human trial visible in public databases as of July 2026. These compounds are not approved as drugs, foods, or dietary supplements, and they are not subject to the manufacturing, labeling, or safety standards that apply to regulated products.

Classification: In most jurisdictions where these compounds are commercially available, they are classified as research chemicals not approved for human therapeutic use. Selling research chemicals is generally legal in many jurisdictions, but representing them for human consumption or therapeutic purposes is not consistent with their regulatory classification.

WADA / USADA status: SLU-PP-332 and BAM15 are not explicitly named on the current WADA prohibited list based on available sources reviewed as of July 2026. The absence of explicit naming does not guarantee they are permitted in sport. WADA's prohibited list includes broad category language (including metabolic modulators and substances with performance-enhancing potential) that could encompass these compounds even without explicit naming. SLU-PP-332's mechanism as an exercise mimetic that activates metabolic gene programs, and BAM15's mechanism as an agent that increases energy expenditure, are both mechanistically aligned with the type of compound WADA has historically sought to prohibit. Athletes subject to anti-doping testing should consult their sport's anti-doping authority before using either compound.

Country-specific notes: No country-specific regulatory analysis beyond the general classification described above is available from reviewed sources. Availability appears to vary by jurisdiction, with some vendors operating from outside the United States. Users are responsible for understanding the regulatory status of these compounds in their specific location before purchase or use.

Detection: No validated WADA-approved test for SLU-PP-332 or BAM15 has been identified in available sources. Whether anti-doping authorities are actively developing detection methods for either compound is not known.

Comparisons & Alternatives

Commonly Paired With: Synergistic Stacks

• SLU-PP-332 + BAM15: This is the primary combination addressed in this article. The theoretical basis is mechanistic complementarity: ERRalpha activation builds metabolic machinery upstream while mitochondrial uncoupling drives increased substrate throughput downstream. No peer-reviewed study has validated whether this combination produces synergistic, additive, or simply redundant effects in humans.

• SLU-PP-332 + 5-Amino-1MQ + BPC-157: Referenced in metabolic health and weight loss contexts in secondary sources. 5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase, an enzyme that consumes a key precursor to NAD+, the molecule cells use to produce energy), which affects NAD+ availability and fat cell differentiation. BPC-157 contributes gut integrity and systemic tissue repair support. The combination targets overlapping aspects of metabolic health from three different angles. Evidence for this specific stack is blog-level commentary only.

• SLU-PP-332 + GLP-1 agonists: Mentioned in metabolic health discussions as a potential complement to GLP-1-based weight management, with SLU-PP-332 adding an energy expenditure mechanism to the appetite and satiety effects of GLP-1 agonism. No clinical data supports this combination.

Alternatives: When Another Compound May Be Considered

MOTS-c MOTS-c is a mitochondria-derived peptide (an actual peptide, unlike SLU-PP-332) that activates AMPK and produces exercise-mimetic metabolic effects through a different pathway. Both are framed as metabolic activators, but MOTS-c works through AMPK rather than ERRalpha. Its amino acid composition means it requires injectable delivery rather than oral capsules. Someone drawn to SLU-PP-332 for its oral availability and exercise-mimetic framing might compare it to MOTS-c for the longevity angle, with the trade-off being administration route.

5-Amino-1MQ 5-Amino-1MQ targets NNMT inhibition, preserving NAD+ availability and inhibiting fat cell differentiation. It shares the metabolic health and fat loss space with SLU-PP-332 but works through a completely different pathway. The two are sometimes stacked rather than substituted. As a standalone alternative, 5-Amino-1MQ may be considered by someone more focused on the NAD+ and fat cell differentiation angle than the ERRalpha activation angle.

O-304 O-304 is an AMPK activator with exercise-mimetic research behind it, appearing in comparative discussions with SLU-PP-332 in secondary sources. The mechanistic difference is AMPK activation versus ERRalpha agonism (overlapping downstream effects through different upstream targets). O-304 has been noted as a candidate for early clinical investigation, though no completed human trial has been identified.

Comparison table:

Build Your SLU-PP-332 and BAM15 Protocol

FAQs

What are SLU-PP-332 and BAM15?

SLU-PP-332 and BAM15 are two small-molecule research chemicals, not peptides, that are frequently discussed together in metabolic health and biohacking contexts. SLU-PP-332 is a synthetic estrogen-related receptor alpha (ERRalpha) agonist that activates metabolic gene programs associated with aerobic exercise, while BAM15 is a mitochondrial uncoupling agent that increases energy expenditure by dissipating the proton gradient across the inner mitochondrial membrane. They are not approved for human therapeutic use by any regulatory agency.

What do SLU-PP-332 and BAM15 do?

SLU-PP-332 activates ERRalpha, a nuclear receptor that controls genes governing fat burning, mitochondrial biogenesis, and aerobic energy production, essentially turning on metabolic programs that exercise normally activates. BAM15 increases energy expenditure by causing mitochondria to burn more fuel without capturing all of it as ATP, releasing the difference as heat. Together, the combination is theorized to increase overall energy expenditure and fatty-acid oxidation through complementary mechanisms, though this synergy has not been validated in controlled human research.

How long does SLU-PP-332 and BAM15 take to work?

Based on anecdotal user reports, thermogenic effects from BAM15 (including increased warmth and perspiration) are sometimes noticed within the first few days. Metabolic and body composition changes, if they occur, appear to be reported over 4 to 12 weeks in community protocol logs. No peer-reviewed study has measured the timing of human outcomes for either compound; the only structured duration data comes from 28-day and 8-week mouse studies.

What is the typical dose of SLU-PP-332 and BAM15?

No validated human dose has been established through clinical research for either compound. The standard commercial capsule blend contains 250 mcg SLU-PP-332 and 50 mg BAM15 per capsule, and one to two capsules daily is the most common anecdotal starting reference. Animal study doses are not directly applicable to humans. Any dose discussion for these compounds is anecdotal, not evidence-based.

Are SLU-PP-332 and BAM15 legal?

In most jurisdictions where they are commercially available, SLU-PP-332 and BAM15 are classified as research chemicals not approved for human therapeutic use. Selling them as research chemicals is generally not prohibited, but they are not approved as drugs or dietary supplements. Neither compound is explicitly named on the current WADA prohibited list, though athletes should be aware that category-level anti-doping risk may exist. Regulatory status varies by country and users are responsible for verifying the rules in their specific jurisdiction.

Can SLU-PP-332 and BAM15 be taken orally?

Yes, and oral administration is the only commercially documented route for both compounds. Unlike peptides (which are degraded by gastric acid and require injection to reach systemic circulation), SLU-PP-332 and BAM15 are small molecules designed for oral delivery. The primary preclinical studies administered SLU-PP-332 orally and achieved measurable systemic effects, confirming oral bioavailability in the animal model. No injectable, nasal, or topical formulations have been identified in current market research.

Why are they called peptides if they are not actually peptides?

The "peptide" label in market discussions around SLU-PP-332 and BAM15 reflects how these compounds are sold and categorized commercially, not their actual molecular classification. Both are small-molecule research chemicals; they do not have amino acid sequences and are not structurally related to peptides. They are discussed alongside peptide therapies because they target overlapping goals (metabolic health, fat loss, longevity) and are sold through similar research chemical channels. The distinction matters primarily for understanding why oral bioavailability works for these compounds when it does not for actual peptides.

Is BAM15 dangerous like DNP?

BAM15 and DNP are both mitochondrial uncouplers, but they are structurally distinct and BAM15 is claimed to have a significantly higher safety margin in preclinical work. DNP was banned after causing deaths primarily through uncontrolled hyperthermia; its uncoupling effect was too severe and too difficult to dose safely. Preclinical data suggests BAM15 has a wider margin between effective and toxic doses, but this distinction has not been validated in human clinical trials. The class-level risk of excessive thermogenesis from any mitochondrial uncoupler is real, and combining BAM15 with other thermogenic compounds amplifies that risk.

What happens if you stop SLU-PP-332 and BAM15?

No published data documents what happens when either compound is discontinued in humans. Mechanistically, the effects of both compounds are dependent on their continued presence: SLU-PP-332 activates ERRalpha only while the compound is present, and BAM15's uncoupling effect ends when the compound clears the system. There is no documented evidence of physical dependence, withdrawal, or rebound effects in the available preclinical or anecdotal literature, though the absence of documentation is not the same as confirmation of safety.

Do SLU-PP-332 and BAM15 work without diet and exercise?

Preclinical mouse data for SLU-PP-332 showed reduced adiposity and improved glucose tolerance without changes in food intake or physical activity, meaning the metabolic effects were observed independently of behavioral changes. Whether this translates to meaningful body composition changes in humans eating normally in a real-world environment is unknown. Anecdotal user reports suggest that results are considerably more pronounced when these compounds are combined with caloric control and exercise, which is consistent with how most metabolic interventions work in practice.

Final Thoughts

SLU-PP-332 and BAM15 represent a genuinely novel category in the metabolic research space: two small-molecule compounds that target energy expenditure from different mechanistic angles. SLU-PP-332 works upstream at the level of gene activation; BAM15 works downstream at the mitochondrial membrane. The preclinical data for SLU-PP-332, while limited to animal models, is real peer-reviewed science showing meaningful metabolic effects in obese mice: reduced fat mass, improved glucose tolerance, increased resting energy expenditure, all without changes in food intake or lean tissue. That is a compelling mechanistic picture, and it is easy to understand why the "exercise mimetic" framing generated significant attention when University of Florida coverage brought it to a broader audience in 2023. BAM15 adds a complementary thermogenic mechanism that makes intuitive sense as a pairing.

The evidence gap between that theoretical case and validated human outcomes is substantial. No human clinical trial has been completed for either compound. No pharmacokinetic data exists for humans. No validated dose has been established. No combination study has tested whether the theoretical synergy is real, redundant, or carries interaction risks that preclinical data did not reveal. The molecular formula of SLU-PP-332 is not even agreed upon between major research suppliers. Anyone using these compounds is working at the frontier of self-experimentation. The combination has not been through the research pipeline that would answer the questions that matter most: how much, for how long, with what effects, in which populations, and with what risks. That frontier deserves honest acknowledgment.

For anyone tracking this space with genuine interest, these compounds are worth following as the research develops. If you are considering protocol use now, three resources matter most. First, independent third-party testing documentation from any supplier you consider. Second, consultation with a healthcare provider who can contextualize the preclinical data against your specific health situation. Third, a protocol framework that accounts for the real uncertainty in dosing and timing. That is exactly what MyPeptidePal is designed to help with.

References

1. Billon, C., et al. (2024). A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics.

2. University of Florida News. (2023, September). Exercise-mimicking drug shows promise in preclinical research. University of Florida News.

3. Bio-Techne / Tocris. SLU-PP-332 compound profile and technical data.

4. Cayman Chemical. SLU-PP-332 product insert and technical documentation.

Additional sources pending editorial review.

Additional sources pending editorial review.